442 related articles for article (PubMed ID: 25227930)
1. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.
Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ
AIDS; 2016 Feb; 30(4):591-600. PubMed ID: 26825032
[TBL] [Abstract][Full Text] [Related]
4. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
Gutiérrez C; Díaz L; Vallejo A; Hernández-Novoa B; Abad M; Madrid N; Dahl V; Rubio R; Moreno AM; Dronda F; Casado JL; Navas E; Pérez-Elías MJ; Zamora J; Palmer S; Muñoz E; Muñoz-Fernández MÁ; Moreno S
PLoS One; 2011; 6(12):e27864. PubMed ID: 22174752
[TBL] [Abstract][Full Text] [Related]
5. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
6. Effect of maraviroc on HIV disease progression-related biomarkers.
Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
[TBL] [Abstract][Full Text] [Related]
7. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.
DʼAntoni ML; Paul RH; Mitchell BI; Kohorn L; Fischer L; Lefebvre E; Seyedkazemi S; Nakamoto BK; Walker M; Kallianpur KJ; Ogata-Arakaki D; Ndhlovu LC; Shikuma C
J Acquir Immune Defic Syndr; 2018 Sep; 79(1):108-116. PubMed ID: 29781885
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Patro SC; Azzoni L; Joseph J; Fair MG; Sierra-Madero JG; Rassool MS; Sanne I; Montaner LJ
J Leukoc Biol; 2016 Jul; 100(1):223-31. PubMed ID: 26609048
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
[TBL] [Abstract][Full Text] [Related]
11. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain.
Kelly KM; Beck SE; Metcalf Pate KA; Queen SE; Dorsey JL; Adams RJ; Avery LB; Hubbard W; Tarwater PM; Mankowski JL
AIDS; 2013 Nov; 27(18):F21-8. PubMed ID: 24051706
[TBL] [Abstract][Full Text] [Related]
13. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Minami R; Takahama S; Kaku Y; Yamamoto M
J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
[TBL] [Abstract][Full Text] [Related]
14. CCR2 on Peripheral Blood CD14
Veenstra M; Byrd DA; Inglese M; Buyukturkoglu K; Williams DW; Fleysher L; Li M; Gama L; León-Rivera R; Calderon TM; Clements JE; Morgello S; Berman JW
J Neuroimmune Pharmacol; 2019 Mar; 14(1):120-133. PubMed ID: 29981000
[TBL] [Abstract][Full Text] [Related]
15. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
Shikuma CM; Wojna V; De Gruttola V; Siriwardhana C; Souza SA; Rodriguez-Benitez RJ; Turner EH; Kallianpur K; Bolzenius J; Chow D; Matos M; Shiramizu B; Clements DM; Premeaux TA; Ndhlovu LC; Paul R
AIDS; 2023 Nov; 37(13):1987-1995. PubMed ID: 37418541
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
18. Neurocognition with maraviroc compared with tenofovir in HIV.
Robertson KR; Miyahara S; Lee A; Brown TT; Chan ES; Berzins B; Rusin D; Eron JJ; Taiwo BO;
AIDS; 2016 Sep; 30(15):2315-21. PubMed ID: 27333088
[TBL] [Abstract][Full Text] [Related]
19. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
Rusconi S; Vitiello P; Adorni F; Colella E; Focà E; Capetti A; Meraviglia P; Abeli C; Bonora S; D'Annunzio M; Di Biagio A; Di Pietro M; Butini L; Orofino G; Colafigli M; d'Ettorre G; Francisci D; Parruti G; Soria A; Buonomini AR; Tommasi C; Mosti S; Bai F; Di Nardo Stuppino S; Morosi M; Montano M; Tau P; Merlini E; Marchetti G
PLoS One; 2013; 8(11):e80157. PubMed ID: 24244635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
